lamifiban has been researched along with 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carroll, RC; Kouns, WC; Lanza, F; Steiner, B; Wang, XF | 1 |
1 other study(ies) available for lamifiban and 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
Article | Year |
---|---|
Blocking platelet aggregation inhibits thromboxane A2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A2.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetates; Adenosine Diphosphate; Blood Platelets; Cytoplasmic Granules; Cytosol; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lysophospholipids; Peptide Fragments; Phosphorylase a; Phosphorylation; Plasma; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Serotonin; Thrombasthenia; Thromboxane A2; Tyrosine; Vasoconstrictor Agents | 1997 |